Hemispherx BioPharma, Inc (NYSE MKT:HEB) recently hosted a Stockholder Open House in their manufacturing and Research and Development (R&D) facility in New Brunswick, NJ, showcasing its progress on all fronts and the near completion of its Alferon® manufacturing program as well as developments in its Ampligen® R&D program. During the tour, stockholders were taken throughout the Alferon® and Ampligen® manufacturing suites and also visited our Research and Development labs, where there has been a significant amount of resources spent on developing a biomarker for Ampligen® to treat Chronic Fatigue Syndrome (CFS). It was emphasized that to achieve accelerated commercial success in the short term, additional funding will be required to go from completion of construction to final Food and Drug Administration (FDA) approval of the Alferon® facility. Consistent with that, all available corporate resources must be directed to achieving this approval. Accordingly, all executive bonus programs, including contract bonuses, have been deferred until these Alferon® manufacturing goals have been achieved and adequate funds are generated to meet our additional research needs for our experimental therapeutic Ampligen®. (Original Source)
Shares of Hemispherx Biopharma closed last Friday at $0.161. HEB has a 1-year high of $0.40 and a 1-year low of $0.14. The stock’s 50-day moving average is $0.19 and its 200-day moving average is $0.22.
Hemispherx Biopharma Inc is a specialty pharmaceutical company. It is engaged in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders.